Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Induction Chemo + Haploidentical Stem Cells for Elderly AML
NCT02519712Terminated
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Jul 2015
- Primary completion
- Sep 2017
- Countries
- 1
01
Overview
Open-label, single-arm trial in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoint: Complete Remission at 4 weeks. Started Jul 2015; status: terminated.
02
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT02519712.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02519712.